The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Kiniksa Pharmaceuticals International Plc shares valued at $835,555 were sold by Quart Barry D on Dec 15 ’25. At $41.51 per share, Quart Barry D sold 20,129 shares. The insider’s holdings dropped to 12,546 shares worth approximately $0.53 million following the completion of this transaction.
Also, Tessari Eben sold 12,048 shares, netting a total of over 500,715 in proceeds. Following the sale of shares at $41.56 each, the insider now holds 16,666 shares.
Before that, Quart Barry D had added 58,889 shares to its account. In a trade valued at $2,444,530, the Director bought Kiniksa Pharmaceuticals International Plc shares for $41.51 each.
As published in their initiating research note from TD Cowen on September 29, 2025, Kiniksa Pharmaceuticals International Plc [KNSA] has been a Buy and the price target has been revised to $60. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March. As of September 13, 2024, Jefferies has initiated its “Buy” rating for KNSA. Earlier on May 03, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for KNSA stock.
Analyzing KNSA Stock Performance
On last trading session, Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] rose 1.28% to $42.0. The stock’s lowest price that day was $40.8, but it reached a high of $42.47 in the same session. During the last five days, there has been a surge of approximately 2.41%. Over the course of the year, Kiniksa Pharmaceuticals International Plc shares have jumped approximately 106.69%. Shares of the company reached a 52-week high of $42.98 on 11/26/25 and a 52-week low of $17.82 on 01/13/25.
Support And Resistance Levels for Kiniksa Pharmaceuticals International Plc (KNSA)
According to the 24-hour chart, there is a support level at 41.02, which, if violated, would cause prices to drop to 40.05. In the upper region, resistance lies at 42.72. The next price resistance is at 43.45. RSI (Relative Strength Index) is 58.85 on the 14-day chart, showing neutral technical sentiment.
Is Kiniksa Pharmaceuticals International Plc subject to short interest?
Stocks of Kiniksa Pharmaceuticals International Plc saw a sharp steep in short interest on 2025-11-28 dropping by 26007.0 shares to 2.8 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 2.83 million shares. A decline of -0.93% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.28 of the overall float, the days-to-cover ratio (short ratio) decline to 6.28.
Which companies own the most shares of Kiniksa Pharmaceuticals International Plc (KNSA)?
In terms of Kiniksa Pharmaceuticals International Plc share price expectations, FactSet research, analysts set an average price target of 54 in the next 12 months, up nearly 30.21% from the previous closing price of $41.47. Analysts anticipate Kiniksa Pharmaceuticals International Plc stock to reach 55 by 2025, with the lowest price target being 44. In spite of this, 1 analysts ranked Kiniksa Pharmaceuticals International Plc stock as Buy at the end of 2025. On June 29, 2020, BofA Securities assigned a price target of “a Buy” to the stock and reiterated coverage with a $40.
